Cabotegravir; Rilpivirine
Sold as Cabenuva. Every branded application for this active ingredient.
- First approved: Jan 21, 2021
- Branded applications: 1
- New uses approved: 6
- Complete response letters: 1
Applications
NDAs and BLAs for this ingredient, oldest first; each opens its full history| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jan 21, 2021 | CabenuvaNDA 212888 · New molecular entity, new combination | Viiv Hlthcare | 10 | Marketed |
Complete Response Letters
FDA's published letters for these applications| Letter | Product | Now |
|---|---|---|
| Dec 19, 2019 | NDA 212888Product Quality/Facility Inspections, Product Quality | Approved |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Drugs@FDA